Drugs / Hillchol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05732766 | Feb → Mar 2023 | cholera | Bharat Biotech International Limited | Unknown | No outcome recorded |
| Phase 3 | NCT05507229 | Feb → Jul 2022 | cholera | Bharat Biotech International Limited | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-27 | Bharat Biotech International Limited | Bharat Biotech Launches Next Generation Oral Cholera Vaccine HILLCHOL�; Expands Manufacturing to Address Global Shortage bharatbiotech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hillchol | “To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)” NCT05732766 ↗ |
| Known as | BBV131 | “Hillchol®(BBV131) vaccine - (Lot-I ) administered to 450 subjects on day 0 and 14.” NCT05507229 ↗1“To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)” NCT05732766 ↗ |
| Modality | Vaccine | “single strain oral cholera vaccine Hillchol® (BBV131)” NCT05507229 ↗ |
| Route | Oral | “single strain oral cholera vaccine Hillchol® (BBV131)” NCT05507229 ↗ |